Loading
Most of the world's cancer patients live in countries that host almost no registrational trials. Including sites there, and paying to build them up, would make results apply globally and speed local access.
Regulators and funders expect global pivotal trials to include a minimum share of sites in low- and middle-income countries, with sponsors funding site capacity (training, pharmacy, imaging, data systems) that persists after the trial. Post-trial access to the drug in participating countries is a condition. Latin American and Indian networks have demonstrated high-quality accrual; African oncology trial infrastructure is the least developed and would be prioritised.
Shares Carlos Barrios, Sudeep Gupta, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, International Agency for Research on Cancer (IARC / WHO), Trials do not represent the people who get cancer.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares Tata Memorial Centre, International Agency for Research on Cancer (IARC / WHO), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Most of the world has almost no cancer care.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares International Agency for Research on Cancer (IARC / WHO), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Most of the world has almost no cancer care.